Noxopharm initiates Phase Ib trial of NOX66 for prostate cancer

Australia-based Noxopharm has initiated a Phase Ib clinical trial of NOX66 in metastatic castrate-resistant prostate cancer patients who do not have remaining standard therapeutic options.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer at ASCO 2018. Author: obr Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Tomasz M. Beer, MD, explains how to avoid under diagnosing and over diagnosing prostate cancer at ASCO 2018. Author: obr Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Tomasz M. Beer, MD, explains the central themes regarding prostate cancer here at ASCO 2018. Author: obr Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Abstract OBJECTIVES: The aim of this study is to test the association between dietary flavonoids intake and prostate cancer (PCa) in a sample of southern Italian individuals. DESIGN: A population-based case-control study on the association between PCa and dietary factors was conducted from January 2015 to December 2016, in a single institution. SETTING: Patients with elevated PSA (Prostate Specific Antigen) and/or suspicion of PCa underwent transperineal prostate biopsy (≥12 cores). A total of 118 histopathological-verified PCa cases were collected and matched with controls, which were selected from a...
Source: Complementary Therapies in Medicine - Category: Complementary Medicine Authors: Tags: Complement Ther Med Source Type: research
Celestia S. Higano, MD, shares her thoughts on how immunotherapy is currently being integrated into castrate resistant prostate cancer treatment algorithms at ASCO 2018. Author: obr Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
(CNN) — People who eat dinner before 9 p.m. — or at least two hours before going to sleep — have a 20% lower risk of breast and prostate cancer than those who eat after 10 p.m. or go to bed shortly after supper, researchers found. “The mechanisms are not clear,” said Dr. Manolis Kogevinas, a research professor at the Barcelona Institute for Global Health in Spain and lead author of a new study on the topic. “What we know from experimental studies is that we are conditioned to function in different parts of the day. We — not only humans but all living organisms — have develope...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Cancer Local TV Source Type: news
In this study, combined reverse pharmacophore mapping, reverse docking, and text-based database search identified Inositol Trisphosphate 3-Kinase (ITP3K-A), Glutamate carboxypeptidase II (GCPII), Leukotriene-A4 hydrolase (LTA4H), Phosphoserine phosphatase (HPSP), Phosphodiesterase 4D (PDE4D), AMPA receptor (GluA3 and GluA2 subunits) and Kainate receptor (GluK1 isoform) as potential targets for Indicaxanthin. These targets are implicated in neuromodulation, and inflammatory regulation, normally expressed mostly in the CNS, and expressed (or overexpressed) in cancer tissues (i.e. breast, thyroid, and prostate cancer cells). ...
Source: Journal of Theoretical Biology - Category: Biology Source Type: research
Conclusions: Although IOP significantly increased during RALP, there were no significant changes in the retinal structure and function between the pre- and postoperation observations. PMID: 30009047 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
Only a small minority of prostate cancer patients benefit from immunotherapy. Gerhardt Attard, MD, PhD, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, spoke to us at the UK Oncology Foru... Author: VJOncology Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
The molecular signatures of tumor cells are often used to select patients for clinical trial recruitment. In this video, Gerhardt Attard, MD, PhD, FRCP, of the Royal Marsden NHS Foundation Trust, Lond... Author: VJOncology Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Australia Health | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals | Prostate Cancer